Enrichment of clonal neoantigens in lesions enhanced the sensitivity of patients with NSCLC or melanoma to anti‐PD‐1 and anti‐CTLA‐4 therapy and promoted overall survival in patients with lung adenocarcinomas.31 This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.